Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - roztrúsená skleróza - selektívne imunosupresíva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - kura - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - aminokyselinový metabolizmus, vrodené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresíva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - glykogénová choroba typu ii - ostatné produkty tráviaceho traktu a metabolizmu - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imunosupresíva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

johnson & johnson santé beauté france s.a.s. routhe de rétortat 51120 sézanne francúzsko -

Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazol - schizophrenia; bipolar disorder - psycholeptika - aripiprazol mylan pharma je indikovaný na liečbu schizofrénie u dospelých a u dospievajúcich vo veku 15 rokov a starších. aripiprazole mylan pharma je indikovaný na liečbu stredne závažných manických epizód v bipolárna som porucha a prevencie nový manické epizódy u dospelých, ktorí zažili prevažne manické epizódy a ktorých manické epizódy reagoval na aripiprazole liečba. aripiprazole mylan pharma je indikovaný na liečbu až 12 týždňov stredne závažných manických epizód v bipolárna som porucha u dospievajúcich vo veku 13 rokov a starších.